Jefferies lifts target for Amgen stock to USD 428.00

Published on 10/27/2026 at 16:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen reported USD 10.05 billion revenue in the second quarter. Amgen stock costs EUR 401.40 on October 27, 2026, up 1.68 percent versus Xetra close.

Analyst target and quarterly revenue

Jefferies raised its Amgen target from USD 410.00 to USD 428.00 on October 26, 2026.
Amgen reported USD 10.05 billion revenue in the second quarter of 2026.
Amgen stock costs EUR 401.40 at Lang & Schwarz on October 27, 2026 at 4:01 p.m. CET, 1.68 percent above the Xetra close of October 26, 2026.

Amgen, US0311621009, Illustration mit AI erstellt.

Jefferies raised its Amgen price target from USD 410.00 to USD 428.00 on October 26, 2026, according to Yahoo Finance. The revised target sits 4.25 percent below Amgen's Nasdaq price of USD 447.00 on October 27, 2026 at 11:04 a.m. EDT. Amgen stock was trading at EUR 401.40 at Lang & Schwarz on October 27, 2026 at 4:01 p.m. CET, 1.68 percent above the Xetra close of October 26, 2026 at EUR 394.75.

Revenue reached USD 10.05 billion

Amgen's second-quarter 2026 revenue reached USD 10.05 billion, up 9.50 percent from the year-earlier comparison. The company also reported USD 2.38 billion in consolidated net income and diluted earnings per share of USD 4.37 for the period.

MarketBeat reported that the second-quarter revenue exceeded consensus of USD 9.43 billion, while earnings per share exceeded the USD 5.62 estimate in its adjusted comparison. The revenue figure gives the analyst target revision a stronger operating reference, but the two measures use different reporting bases.

Amgen stays near its yearly high

On Nasdaq, Amgen's October 27 price of USD 447.00 stood 0.88 percent below its 52-week high of USD 450.98 and 55.21 percent above its 52-week low of USD 288.00. The company's market capitalization was USD 241.7 billion, with a price-to-earnings ratio of 27.76.

Results date and peer comparison

MarketScreener lists November 3, 2026 as Amgen's next earnings release date. That date gives investors the next scheduled checkpoint for the revised analyst view and for the company's latest operating trends.

Comparison with peers

Amgen: up 1.68 percent versus the Xetra close, P/E 27.76, market capitalization USD 241.7 billion.

Gilead Sciences (Nasdaq, USD): down 0.69 percent on October 27, 2026, P/E negative 59.03, market capitalization USD 195.4 billion.

Regeneron Pharmaceuticals (Nasdaq, USD): up 0.75 percent on October 27, 2026, P/E 20.13, market capitalization USD 83.8 billion.

Target meets a near-high share price

Amgen's revised USD 428.00 target is below the latest Nasdaq price, while the stock remains close to its USD 450.98 yearly high. The upcoming November 3 reporting date may therefore provide the next dated test for revenue growth and valuation.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.